TSR-042

DRUG7 trials

Conditions

Advanced CancerCancer of the EndometriumCervical CancerEndometrial CancerMetastatic CancerNeoplasmsNon Small Cell Lung CancerNon Small Cell Lung Cancer Metastatic

Phase 1

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Active, not recruitingNCT02817633

Tesaro, Inc.Neoplasms

Start: 2016-07-08End: 2027-03-01Updated: 2025-10-28

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

CompletedNCT03307785

Tesaro, Inc.Advanced Cancer, Metastatic Cancer, Neoplasms +4

Start: 2017-10-12End: 2024-12-11Updated: 2025-11-25

TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer

Active, not recruitingNCT03955978

Washington University School of MedicineCancer of the Endometrium, Endometrial Cancer

Start: 2019-10-15End: 2029-02-01Updated: 2026-01-06

Phase 2

Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

Active, not recruitingNCT03016338

University Health Network, TorontoEndometrial Cancer

Start: 2017-11-06End: 2026-12-01Updated: 2026-06-23

A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer

CompletedNCT03574779

Tesaro, Inc.Ovarian Neoplasms

Start: 2018-11-15End: 2025-03-31Updated: 2025-07-15

TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation

Active, not recruitingNCT03833479

Grupo Español de Investigación en Cáncer de OvarioAdvanced Cancer, Cervical Cancer

Start: 2019-06-28End: 2028-07-31Updated: 2026-06-17

Study on TSR-042 in Advanced Clear Cell Sarcoma

TerminatedNCT04274023

Italian Sarcoma GroupSarcoma, Clear Cell

Start: 2024-01-29End: 2024-01-29Updated: 2024-02-01

Clinical Cancer Research2025-06-247 citations

Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B

Clinical Cancer Research2025-06-243 citations

AMBER part 2F: Cobolimab in combination with dostarlimab in treatment-naïve patients with locally advanced/metastatic and/or unresectable hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2025-01-271 citations

Toripalimab combined with definitive chemoradiotherapy for locally advanced cervical squamous cell carcinoma patients (TRACE): A single-arm, phase I/II trial.

2024-10-033 citations

Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study

BMJ Open2024-08-0110 citations

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.

2024-05-041 citations

Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial

JCO Precision Oncology2024-05-019 citations

Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer

Clinical Cancer Research2024-01-028 citations

596 AMBER, Part 2B: a phase 1 study of cobolimab plus dostarlimab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD(L)-1 therapy

Regular and Young Investigator Award Abstracts2023-10-314 citations

Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer.

2023-10-184 citations

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.

2023-03-1518 citations

ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation.

2022-09-0619 citations

Dostarlimab: A Review.

2022-07-2639 citations

Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial.

2022-07-1910 citations

Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER).

Journal of Clinical Oncology2022-06-0172 citations

AMBER parts 1c and 1e: A phase 1 study of cobolimab plus dostarlimab in patients (pts) with advanced/metastatic melanoma.

Journal of Clinical Oncology2022-06-0110 citations

Population pharmacokinetics and exposure–response of anti‐programmed cell death protein‐1 monoclonal antibody dostarlimab in advanced solid tumours

British Journal of Clinical Pharmacology2022-03-3125 citations

IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer

Journal for ImmunoTherapy of Cancer2022-03-0116 citations

Immune Checkpoints are Important Therapeutic Targets in Cancer Immunotherapy

Cancer Science & Research2021-12-30

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006

European Journal of Cancer2021-09-2724 citations

5 more papers not shown

TSR-042

Sponsors

Conditions

Phase 1

Phase 2

Related Papers